Tranche Update on Hugel, Inc.'s Equity Buyback Plan announced on April 7, 2022.
April 06, 2023 at 07:57 am
Share
From July 1, 2022 to September 30, 2022, the company has repurchased 0 shares, representing 0% for KRW 0 million. With this, the company has completed the repurchase of 140,000 shares, representing 1.16% for KRW 17,139.55 million under the buyback announced on April 7, 2022.
Hugel Inc is a Korea-based company mainly engaged in the manufacture of biopharmaceuticals. The Company's product portfolio consists of botulinum toxins which used for treatment of benign essential blepharospasm and temporary improvement of moderate to severe glabellar lines including 50 unit types, 100 unit types and 200unit types; hyaluronic acid (HA) fillers which used for temporary removal of facial wrinkles including the chaeum premium No.1, the chaeum premium No.2, the chaeum premium No.3m the chaeum premium No.4, the chaeum MID 20A, the chaeum DEEP 20A, the chaeum SUB-Q 20A and the chaeum VOLUS 20A; wellages, blue roses and other cosmetics. The Company sells its products in domestic and overseas markets.
HUGEL, INC. 
